Ebola virus disease: A review on epidemiology, symptoms, treatment and pathogenesis

Netherlands Journal of Medicine

Volumn 72, Issue 9, 2014, Pages 442-448

  Goeijenbier, M ^a   van Kampen, J J A ^a   Reusken, C B E M ^a   Koopmans, M P G ^a,b   van Gorp, E C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Ebola virus disease; Filovirus; Pathogenesis; Treatment; Viral haemorrhagic fever

Indexed keywords

ANTIVIRUS AGENT; AVI 6002; FAVIPIRAVIR; IMMUCILLIN A; RIBAVIRIN; TKM 100802; UNCLASSIFIED DRUG; ZMAPP;

ARTICLE; BIOLOGICAL ACCIDENT; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; EBOLA HEMORRHAGIC FEVER; GENE SILENCING; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOTHERAPY; NONHUMAN; PROTECTIVE EQUIPMENT; VIRUS PATHOGENESIS; AFRICA; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA; TRANSMISSION; VIROLOGY;

AFRICA, WESTERN; DISEASE OUTBREAKS; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84930189911     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Briand S, Bertherat E, Cox P, et al. The International Ebola Emergency. N Engl J Med. 2014;371:1180-3.
2. Leroy EM, Labouba I, Maganga GD, Berthet N. Ebola in West Africa: The outbreak able to change many things. Clin Microbiol Infect. 2014 [Epub ahead of print].
3. http://apps.who.int/iris/bitstream/10665/133833/1/roadmapsitrep4_eng. pdf?ua=1.
4. Nunes-Alves C. Ebola update. Nat Rev Microbiol. 2014;12:656.
5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849-62.
6. Johnson KM, Lange JV, Webb PA, Murphy FA. Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire. Lancet. 1977;1:569-71.
7. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola Virus Disease in Guinea – Preliminary Report. N Engl J Med. 2014;371:1418-25.
8. Paessler S, Walker DH. Pathogenesis of the viral hemorrhagic fevers. Annu Rev Pathol. 2013;8:411-40.
9. Goeijenbier M, Wagenaar J, Goris M, et al. Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable – epidemiology, diagnostics and treatment. Crit Rev Microbiol. 2013;39:26-42.
10. Le GB, Formenty P, Wyers M, Gounon P, Walker F, Boesch C. Isolation and partial characterisation of a new strain of Ebola virus. Lancet. 1995;345:1271-4.
11. Cox NJ, McCormick JB, Johnson KM, Kiley MP. Evidence for two subtypes of Ebola virus based on oligonucleotide mapping of RNA. J Infect Dis. 1983;147:272-5.
12. Muyembe-Tamfum JJ, Mulangu S, Masumu J, Kayembe JM, Kemp A, Paweska JT. Ebola virus outbreaks in Africa: past and present. Onderstepoort J Vet Res. 2012;79:451.
13. Gire SK, Goba A, Andersen KG, et al. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science. 2014;345:1369-72.
14. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438:575-6.
15. Leroy EM, Epelboin A, Mondonge V, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. 2009;9:723-8.
16. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol. 2014;95:1619-24.
17. Bausch DG, Bangura J, Garry RF, et al. A tribute to Sheik Humarr Khan and all the healthcare workers in West Africa who have sacrificed in the fight against Ebola virus disease: Mae we hush. Antiviral Res. 2014;111C:33-5.
18. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014--new challenges, new global response and responsibility. N Engl J Med. 2014;371:1177-80.
19. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204:S810-6.
20. Jeffs B. A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa. Trop Doct. 2006;36:1-4.
21. Hartman AL, Towner JS, Nichol ST. Ebola and Marburg hemorrhagic fever. Clin Lab Med. 2010;30:161-77.
22. Baize S, Leroy EM, Georges-Courbot MC, et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med. 1999;5:423-6.
23. Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E. Early immune responses accompanying human asymptomatic Ebola infections. Clin Exp Immunol. 2001;124:453-60.
24. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis. 1999;179:S28-35.
25. McElroy AK, Erickson BR, Flietstra TD, et al. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210:558-66.
26. Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E. Inflammatory responses in Ebola virus-infected patients. Clin Exp Immunol 2002;128:163-8.
27. Baize S, Pannetier D, Oestereich L, et al. Emergence of Zaire Ebola Virus Disease in Guinea – Preliminary Report. N Engl J Med. 2014;371:1418-25.
28. WHO situation report http://apps.who.int/iris/bitstream/10665/133833/1/ roadmapsitrep4_eng.pdf?ua=1
29. Miranda ME, Miranda NL. Reston ebolavirus in humans and animals in the Philippines: a review. J Infect Dis. 2011;204:S757-60.
30. Hofmann-Winkler H, Kaup F, Pohlmann S. Host cell factors in filovirus entry: novel players, new insights. Viruses. 2012;4:3336-62.
31. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog. 2007;3:e2.
32. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. 2008;26:6894-900.
33. Leroy EM, Gonzalez JP, Baize S. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa. Clin Microbiol Infect. 2011;17:964-76.
34. Bray M, Hatfill S, Hensley L, Huggins JW. Haematological, biochemical and coagulation changes in mice, guinea-pigs and monkeys infected with a mouse-adapted variant of Ebola Zaire virus. J Comp Pathol. 2001;125:243-53.
35. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. 2004;4:487-98.
36. Goeijenbier M, van Wissen M, van de Weg C, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012;84:1680-96.
37. Geisbert TW, Young HA, Jahrling PB, et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Am J Pathol. 2003;163:2371-82.
38. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188:1618-29.
39. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J Virol. 2003;77:7539-44.
40. Nakayama E, Tomabechi D, Matsuno K, et al. Antibody-dependent enhancement of Marburg virus infection. J Infect Dis. 2011;204:S978-85.
41. Mairuhu AT, MacGillavry MR, Setiati TE, et al. Is clinical outcome of dengue-virus infections influenced by coagulation and fibrinolysis? A critical review of the evidence. Lancet Infect Dis. 2003;3:33-41.
42. van Gorp EC, Setiati TE, Mairuhu AT, et al. Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever. J Med Virol. 2002;67:549-54.
43. Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210-5.
44. Fowler RA, Fletcher T, Fischer Ii WA, et al. Caring for Critically Ill Patients with Ebola Virus Disease: Perspectives from West Africa. Am J Respir Crit Care Med. 2014;190:733-7.
45. Jahrling PB, Geisbert TW, Geisbert JB, et al. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections. J Infect Dis. 1999;179:S224-34.
46. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis. 1989;11:S750-61.
47. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47-53.
48. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104:153-5.
49. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446-54.
50. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17-21.
51. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX 4430. Nature. 2014;508:402-5.
52. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896-905.
53. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991-4.
54. Heald AE, Iversen PL, Saoud JB, et al. Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single Ascending Dose Studies. Antimicrob Agents Chemother. 2014 [Epub ahead of print].
55. Mupapa K, Massamba M, Kibadi K, et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis. 1999;179:S18-S23.
56. Jahrling PB, Geisbert JB, Swearengen JR, Larsen T, Geisbert TW. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J Infect Dis. 2007;196:S400-3.
57. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J Infect Dis. 2006;193:1650-7.
58. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX 4430. Nature. 2014;508:402-5.
59. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother. 2009;53:2089-99.
60. Pettitt J, Zeitlin L, Kim DH, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5:199-133.
61. Leirs H, Mills JN, Krebs JW, et al. Search for the Ebola virus reservoir in Kikwit, Democratic Republic of the Congo: reflections on a vertebrate collection. J Infect Dis. 1999;179:S155-63.